The mdm2 proto-oncogene

Leukemia and Lymphoma

Volumn 26, Issue 3-4, 1997, Pages 227-238

  Haines, Dale S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Mdm2 proto oncogene

Indexed keywords

PROTEIN P53;

CARCINOGENESIS; DNA DAMAGE; DOUBLE MINUTE CHROMOSOME; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TRANSCRIPTION REGULATION;

EID: 0030777230     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709051772     Document Type: Review

References (84)

1. Cahilly-Snyder, L., Yang-Feng, T., Francke, U. and George, D L. (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet., 13, 235-244.
2. Farkharzadeh, S. S., Trusko, S. P. and George, D. L (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in mouse tumor cell line. EMBO J., 10, 1565-1569.
3. Gottlieb, T. M. and Oren, M. (1996) p53 in growth control and neoplasia Biochimica el Biophysica Acta, 1287, 77-102.
4. Kern, S. E., Kinzler. K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. and Vogelstein, B. (1991). Identification of p53 as a sequence-specific DNA binding protein. Science, 252, 1708-1711.
5. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E. and Shay, J. W. (1992). Transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12, 2866-2871.
6. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. and Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nature Genet., 1, 45-49.
7. Farmer, G. E., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R. and Prives, C (1992). Wild-type p53 activates transcription in vitro Nature, 358, 83-86.
8. Zambetti, G. P., Bargonetti, J., Walker. K., Prives, C. and Levine, A. J. (1992). Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes and Develop., 6, 1143-1152.
9. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogehtein, B. (1993). WAFI, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
10. Okamoto, K. and Beach, D. (1994). Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J., 13, 4816-4822.
11. Kastan, M B., Zhan, Q, el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. and Fornace, A. J. Jr. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587-597.
12. Morris, G F., Bischoff, J. R. and Mathews, M. B. (1996). Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl. Acad. Sci. USA, 93, 895-899.
13. Miyashita, T. and Reed, J. C. (1995). Tumor suppressor p53 is a direct transcnptional activator of the human bax gene. Cell, 80, 293-299
14. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B and Levine, A. J. (1990). Mutant p53 DNAs from human colorectal carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth and Diff., 1, 571-580.
15. Barak, Y. and Oren, M. (1992). Enhanced binding of a 95 Kd protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J., 11, 2115-2121.
16. Momand, J., Zambetti, G. P., Olson, D., George, D. L. and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell, 69, 1237-1245.
17. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. and Vogelstein, B. (1992). Amplification of a gene ending a p53 associated protein in human sarcomas Nature, 358, 80-83.
18. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W. and Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
19. Chen, J., Marechal, V. and Levine, A. J. (1993). Mapping of the p53 and mdm2 interaction domains. Mol. Cell Biol., 13, 4107-4114.
20. Lin, J., Chen, J., Elenbaas, B., and Le-ine, A J. (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus S EIB SS-kD protein. Genes and Dev., 8, 1235-1246.
21. Picksley, S. M., Vojtesek, B., Sparks, A. and Lane, D. P. (1994). Immunochemical analysis of the interaction of p53 and mdm2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene, 9, 2523-2529.
22. Fields, S and Jang, S. K. (1990). Presence of a potent transcription activating sequence in the p53 protein. Science, 249, 1046-1049.
23. Zauberman, A., Barak, Y., Ragimov, N., Levy, N. and Oren, M. (1993). Sequence-specific binding DNA binding by p53identification of target sites and lack of binding to p53-Mdm2 complexes EMBO J., 12, 2799-2808.
24. Finlay, C. A. (1993). The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13, 301-306.
25. 1 arrest and apoptosis functions of the p53 tumor suppressor. Mol. Cell Biol., 16, 2445-2452.
26. Haupt, Y., Barak, Y. and Oren, M. (1996). Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J, 15, 1596-1606
27. Chen, C-Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Jr., Vogelstein, B. and Kastan, M. B. (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA, 91, 2684-2688.
28. Kondo, S., Barnett, G. H., Hara. H., Morimura, T. and Takeuchi, J. (1995). MDM2 protein confers resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene, 10, 2001-2006, 1995.
29. Barak. Y., Juven, T., Haffner, R. and Oren, M. (1993). mdm2 expression is induced by wild-type p53 activity. EMBO J., 12, 461-68.
30. Wu, X., Bayle, J. H., Oison, D. and Levine, A. J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes and Dev., 7, 1126-1132.
31. Juven, T., Barak, Y., Zauberman, A., George, D. L. and Oren, M. (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene, 8, 3411-3416.
32. Barak, Y., Gottlieb, E., Juven Gershou, T. and Oren, M. (1994). Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes and Dev., 8, 1739-1749
33. Zauberman, A., Flusberg. D., Haupt, Y., Barak, Y. and Oren, M. (1995). A functional p53-responsive intronic promoter is contained within the human mdm-2 gene. Nucleic Acids Res., 23, 2584-2592.
34. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. and Levine, A J. (1993). The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA, 90, 11623-11627.
35. Allday, M. J., Sinclair. A., Parker, G., Crawford, D. H and Parrell, P. J. (1995). Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J, 14, 1382-1391.
36. Sigalas. I., Calvert, H. A., Andersen, J. J., Neal, D. E. and Lunec, J. (1996). Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Medicine, 2, 912-917.
37. Sheikh, M. S., Shao, Z-M., Hussain, A. and Fontana J. A. (1993). The p53-binding protein MDM2 is differentially expressed in human breast carcinoma. Cancer Res., 53, 3226-3228.
38. Gudas, J. M., Nguyen, H., Klein. R. C., Katayose, D., Seth, P. and Cowan, K. H. (1995) Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells Clinical Cancer Res., 1. 71-80.
39. Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A. and Albitar, M. (1993). The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82, 2617-2623
40. 2 gene is found in some cases of haematological malignancies. Brit. J. Haemalol, 88, 415-418.
41. Watanabe, T., Hotta, T., Ichikawa, A., Kmoshita, T., Nagai, H., Uchida, T., Murale, T. and Saito, H. (1994). The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood, 84, 3158-3165.
42. Marks, D. I., Kurz, B. W., Link, M. P., Ng, E., Shuster, J. J., Lauer, S. J., Brodsky, I. and Haines, D. S. (1996). High incidence of potential p53 pathway inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood, 87, 1155-1161.
43. Leach, F. S., Tokino, T., Meltzer, Burrell, M., Oliner. J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W. and Vogelstein, B. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53, 2231-2234
44. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G. and Healy, J H (1993). MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53, 16-18.
45. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E. and Colhins, V. P. (1993). Amplification and overexpression of the MDM2 gene in a subset of human gliomas without p53 mutations. Cancer Res., 58, 2736-2739.
46. Ladanyi, M., Lewis. R., Jhanwar, S. C., Gerald, W., Huvos, A. G and Healey, J. H. (1995). MDM2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathology, 175, 211-217.
47. McCann, A. H., Kirley. A., Carney, D. N., Corbally, N., Magee, H. M., Keating, G and Dervan, P. A. (1995). Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Bra. J. Cancer, 71, 981-985.
48. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W. J., Takahashi, R., Sugiyama, T. and Yoshida, O. (1994). Oncogene amplification in urothelial cancers with p53 gene mutations or mdm2 overexpression. J. Natl. Cancer Inst., 86, 1331-1335.
49. Vogelstein B. and Kinzler, K. W. (1992). p53 function and dysfunction. Cell, 70, 523-526.
50. Marchetti A., Buttitta, F., Pellegnni S., Merlo G., Chella, A., Angeletti, C. A. and Bevilacqau, G. (1995). mdm2 gene amplification and overexpression in non-small cell lung carcinoma with accumulation of the p53 protein in the absence of p53 gene mutation. Diagnostic Molecular Pathology, 4,93-97.
51. Gelsleichter, L., Gown, A. M., Zaro, R J., Wang, E. and Coltrera, M D. (1995) p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm2, and markers of cell proliferation in primary versus metastatic tumors. Modern Pathology, 8, 530-535.
52. Girod, S. C., Cesarz, D., Fisher, U. and Krueger, G. R. (1995). Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res., 15, 1453-1457.
53. Riou, G., Barrois, M., Prost, S., Terrier, M J, Theodore, C. and Levine, A. J. (1995). The p53 and mdm-2 genes in human testicular germ-cell tumors Molecular Carcinogenesis, 12, 124-131.
54. Lianes, P., Orlow, I., Zhang, Z. F., Olivia, M. R., Sarkins, A. S., Reuter, V. E. and Cordon-Cardo, C. (1994). Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 86, 1325-1330.
55. Cordon-Cardo, C., Latres, E., Drodnjak. M., Olivia, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F. and Levine, A. J. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54, 794-799.
56. Levine, A. J., Momand, J. and Finlay, C. A. (1991). The p53 tumour suppressor gene. Nature, 351, 453-456.
57. Chilosi, M., Doglioni, C., Menestrina, F., Montagne, L., Rigo, A., Lestani, M., Barbareschi, M., Scarpa, A., Mariuzzi, G. M. and Pizzolo, G. (1994). Abnormal expression of the p53 binding protein MDM2 in Hodgkin's disease. Blood, 84, 4295-4300.
58. Ridge, S. A., Dyer, M., Greaves, M. F. and Wiedemann, L. M. (1994). Lack of MDM2 amplification in human leukaemia. Brit. J. Haematol., 86, 407-409.
59. Maestro, R., Gloghini, A., Doglioni, C., Gasparotto, D., Vukosavljevic, T., De Re, V., Laurino, L., Carbone, A. and Boiocchi, M. (1995). MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-hodgkin's lymphomas. Blood, 85, 3239-3246.
60. Martinez, J. C., Mateo, M., Sanchez-Beato, M, Villuendas, R., Orradre, J. L., Algara. P., Sanchez-Verde, L., Garcia, P., Lopez. C., Martinez, P. and Paris, M. A. (1995). MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J. Pathology, 177, 27-34.
61. Marks, D. I., Kurz, B. W., Link. M. P., Ng, E., Shuster, J. J., Lauer, S. J., Carroll, D., Brodsky, I. and Haines, D. S. Altered expression of mdm-2 and p53 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. Manuscript submitted.
62. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. and Jacks, T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
63. Lowe, S. W., Ruley, H. E., Jacks, T. and Houseman, D. E. (1993). p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 80, 957-967.
64. Livingston, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T. and Tlsty, T D (1993) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935
65. Sands, A T., Suraokar, M. B., Sanchez, A., Marth, J. E., Donehower, L. A. and Bradley, A. (1995). p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc. Natl. Acad. Sci USA, 92, 8517-8521
66. Thor, A. F., Moore, D. H. II, Edgerton, S. M., Kawasaki, E. S., Reihsau, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H. and Smith. H. S. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J. Natl. Cancer Inst., 84, 845-855.
67. Kovach, J. S., Hartmann, A., Blaszk, H., Cunningham, J., Schaid, D. and Sommer, S. S. (1996). Mutation detection by highly sensitive methods indicate that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93, 1093-1096.
68. Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P. and Silvestre, F. (1992). p53 expression and prognosis in gastric carcinoma. Int. J. Cancer, 50, 859-862.
69. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., Shimokata, K., Yamakawa, K., Nakamura, Y., Ueda, R and Takahashi, T. (1993). Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53, 1-4.
70. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood, 84, 3148-3157.
71. Montes de Oca Luna, R., Wagner, D. S. and Lozano, G. (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 378, 203-206.
72. Jones, S. N., Roe, A. E, Donehower, L. A., and Bradley, A. (1995). Rescue of early embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 378, 206-208.
73. Cheng, Y. T., Li, Y. L., Wu, J. D., Long, S. B., Tzai, T. S., Tzeng, C. C., and Lai, M. D. (1995). Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma lines. Molecular Carcinogenisis, 13, 173-181.
74. Dubs-Poterszman, M. C., Tocque, B. and Wasylyk, B. (1995). MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogens, 11, 2445-2449.
75. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedl, N., Xing, J., Sellers, W. R. and Livingston, D. M. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375, 694-698.
76. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B. and Kouzarides, T. (1995). Stimulation of E2F1/DP1 activity by MDM2 oncoprotein. Nature, 375, 691-694.
77. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E. and Dyson, N. J. (1996) Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85, 537-548.
78. Field, S J., Tsai, F-Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Jr., Livingston, D. M., Orkin, S. H. and Greenberg, M. E. (1996). E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell, 85, 549-561.
79. Maltzman, W. and Czyzyk. (1984). UV irradiation stimulates levels of the p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4, 1689-1694.
80. Olson, D. C., Marechal, V., Momand, J., Chen, J., Romocki, C. and Levine, A. J. (1993). Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene, 8, 2353-2360.
81. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Huh, Y. O., Keating, M. J. and Albitar, M. (1995). Multiple patterns of MDM-2 deregulation in human leukemias: Implication in leukemogenesis and prognosis. Leukemia and Lymphoma, 17, 13-18.
82. Maxwell, S. A. (1994). Selective compartmentalization of different mdm2 proteins within the nucleus. Anticancer Res., 14, 2541-2548.
83. Haines, D. S., Landers, J. E., Engle, L. J. and George, D. L. (1994). Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol., 41, 1171-1178.
84. Boddy, M N., Freemont, P. S. and Borden, K. L. (1994). The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends in Biochemical Sciences, 19, 198-199.